Research programme: anti-HIV compounds - ViiV HealthcareAlternative Names: BMS 986197
Latest Information Update: 18 Jul 2016
At a glance
- Originator Bristol-Myers Squibb
- Developer ViiV Healthcare
- Class Small molecules
- Mechanism of Action Capsid protein inhibitors; HIV integrase inhibitors; HIV replication inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HIV infections